Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study-Reference-Cited by-同舟云学术

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

Published:2017-10 Issue:10 Volume:2 Page:716-726
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Jones David,Boudes Pol F,Swain Mark G,Bowlus Christopher L,Galambos Michael R,Bacon Bruce R,Doerffel Yvonne,Gitlin Norman,Gordon Stuart C,Odin Joseph A,Sheridan David,Wörns Markus-Alexander,Clark Virginia,Corless Linsey,Hartmann Heinz,Jonas Mark E,Kremer Andreas E,Mells George F,Buggisch Peter,Freilich Bradley L,Levy Cynthia,Vierling John M,Bernstein David E,Hartleb Marek,Janczewska Ewa,Rochling Fedja,Shah Hemant,Shiffman Mitchell L,Smith John H,Choi Yun-Jung,Steinberg Alexandra,Varga Monika,Chera Harinder,Martin Robert,McWherter Charles A,Hirschfield Gideon M

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference46 articles.

1. The immunobiology and pathophysiology of primary biliary cirrhosis;Hirschfield;Annu Rev Pathol,2013

2. Primary biliary cirrhosis;Carey;Lancet,2015

3. Ursodiol for the long-term treatment of primary biliary cirrhosis;Poupon;N Engl J Med,1994

4. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis;Nevens;N Engl J Med,2016

5. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis;Poupon;Gastroenterology,1997

Cited by 117 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitis;American Journal of Physiology-Gastrointestinal and Liver Physiology;2024-02-01

2. Optimal drug regimens for improving ALP biochemical levels in patients with primary biliary cholangitis refractory to UDCA: a systematic review and Bayesian network meta-analysis;Systematic Reviews;2024-01-29

3. Toxicity Assessment of Mixed Exposure of Nine Perfluoroalkyl Substances at Concentrations Relevant to Daily Intake;Toxics;2024-01-10

4. The role of peroxisome proliferator‐activated receptors in the regulation of bile acid metabolism;Basic & Clinical Pharmacology & Toxicology;2023-12-15

5. New Therapies on the Horizon for Primary Biliary Cholangitis;Drugs;2023-12-12